Emiltatug ledadotin (Emi-Le)

Emiltatug ledadotin is investigational. Its anticipated population is locally advanced, recurrent or metastatic ACC with solid histology or high-grade transformation, the population named in the FDA Breakthrough Therapy designation. In current guidelines, systemic therapy for R/M ACC is started when metastases are symptomatic and not amenable to local therapy, threaten organ function, or have grown more than 20% in 6 months; clinical trial participation is the preferred option, followed by multitargeted VEGFR tyrosine kinase inhibitors or platinum-based chemotherapy. No agent is approved or designated as preferred, so emiltatug ledadotin, if approved, would enter a setting without an established first-line systemic standard. Based on the existing sequencing framework, it would most likely be used in progressive or symptomatic aggressive ACC, either before or after a VEGFR tyrosine kinase inhibitor; the ASCO 2026 interim analysis did not define a line of therapy, and the sponsor has stated that a pivotal phase 2 study is planned.

Emiltatug ledadotin is administered intravenously, which places it in a hospital-based or clinic-based infusion setting, in contrast with the oral VEGFR tyrosine kinase inhibitors. Given the rarity of ACC, guideline recommendations for management by multidisciplinary teams in specialized head and neck units apply.